Overview: Myelin-Associated Glycoprotein IgM TestIntroduction: The Myelin-Associated Glycoprotein IgM Test detects MAG IgM antibodies to diagnose neuropathy, causing numbness or weakness. Aligned with 2023 AAN guidelines, it uses immunoassay for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected peripheral neuropathy, particularly MAG-associated neuropathy.
Other Names: MAG IgM Assay, Neuropathy Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: MAG IgM testing began in the 1980s with neuropathy research. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects MAG IgM antibodies to diagnose neuropathy, guides treatment, and evaluates patients with numbness or weakness.
Test Parameters: 1. Myelin Associated Glycoprotein IgM
Pretest Condition: No fasting required. Collect serum or saliva. Report history of numbness, weakness, or neuropathic symptoms.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document numbness, weakness, tingling, or history of autoimmune diseases. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, neuropathy implications, and risks of sample collection.
Procedural Considerations: Uses immunoassay to detect MAG IgM antibodies in serum or saliva. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for neuropathy diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Insufficient sample volume may reduce accuracy.
Clinical Significance: Positive MAG IgM confirms MAG-associated neuropathy, guiding immunosuppressive therapy (e.g., rituximab). Negative results may require further neuropathy testing.
Specialist Consultation: Consult a neurologist for result interpretation and treatment planning.
Additional Supporting Tests: Nerve conduction studies, anti-SGPG IgM, or nerve biopsy to confirm neuropathy diagnosis.
Test Limitations: Not all neuropathies are MAG-associated; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Neuropathy Guidelines, 2023; Neurology, Latov N, 2022.
